IF Lifetime Venture / Incubate Fund General Partner / Associate
・
"French biotech Genfit, one of the leading pack in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial by four to six months in patients with liver scarring."
